Sponsor pipeline

Mirati Therapeutics Inc. clinical trial pipeline

Get alerts when Mirati Therapeutics Inc.'s trials change

8 active trials 3 recruiting 4 Phase 3 3 disease areas 4 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-11

What changed in the last 30 days

3 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 2 with minor changes only.

Notable

SAPPHIRE · Sitravatinib Plus Nivolumab vs Docetaxel · Advanced Non-Squamous Non-Small Cell Lung Cancer

Reclassified as terminated (was completed)

Sponsor's reason: Inability to meet protocol objectives

Mirati Therapeutics Inc.Phase 3 NCT03906071 Registry history of NCT03906071 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026

Show 2 trials with minor changes only

Minor

Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent

Trial completed

Mirati Therapeutics Inc.Phase 1 NCT07723118 Registry history of NCT07723118 on ClinicalTrials.gov (opens the registry)

Updated Sep 28, 2026
Minor

MRTX849 With Cetuximab vs Chemotherapy · Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Completion pushed from Jul 31, 2026 to Oct 23, 2026

Mirati Therapeutics Inc.Phase 3 NCT04793958 Registry history of NCT04793958 on ClinicalTrials.gov (opens the registry)

Updated Sep 28, 2026

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Active trials by phase

Phase 1/2		1
Phase 2		3
Phase 2/3		1
Phase 3		3

Active trials

NCT ID	Title	Condition	Status	Updated
Phase 3
NCT06875310	A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab…	Carcinoma, Non-Small-Cell Lung	Recruiting	2026-09-22
NCT04793958	Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced…	Advanced Colorectal Cancer	Active, Not Recruiting	2026-09-28
NCT04685135	Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small…	Metastatic Non Small Cell Lung Cancer	Active, Not Recruiting	2026-08-11
Phase 2/3
NCT04613596	Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase…	Advanced Non-Small Cell Lung Cancer	Recruiting	2026-09-16
Phase 2
NCT07415031	A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in…	Solid Tumors	Recruiting	2026-10-09
NCT05853575	Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)	Advanced Cancer	Active, Not Recruiting	2026-08-14
NCT05609578	Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C…	Advanced NSCLC	Active, Not Recruiting	2026-06-23
Phase 1/2
NCT03785249	Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1	Advanced Cancer	Active, Not Recruiting	2026-07-29

Disease areas by active trials

Lung Cancer (5) · Non-Small Cell Lung Cancer (NSCLC) (4) · Colorectal Cancer (1)

Get alerts when Mirati Therapeutics Inc.'s trials change

Status changes, date slips, and new filings: detected daily, delivered to your inbox.

Start monitoring free